위선암종에서 p53 및 MDM-2단백 발현과 임상병리학적 인자들과의 상관관계

Abstract

Purpose :MDM-2 is an oncoprotein that inhibits p53 tumor-suppressor protein. These abnormalities have a role in tumorigenesis through inactivation of p53 function. To determine the clinicopathological and prognostic value of MDM2 abnormalities in gastric adenocarcinoma, MDM2 & p53 protein expression were analysed in surgically resected materials of gastric adenocarcinoma. Materials and Methods :Fifty cases which had got follow-up after surgical resection were immunohistochemically studied with p53 and MDM-2 antibodies. We defined variable clinicopathologic factors for expression of p53 and MDM-2 protein and analysed their relationships. Results :Immunohistochemical stain revealed expression of MDM-2 protein as a 52.0% (26/50) and p53 protein 20.0% (10/50), respectively. But their expressions were not associated with clinicopathological factors such as T-factor, N-factor, stage, histology and differentiation. Overall, p53-negative patients seemed to have a better prognosis regardless of MDM-2 protein status (P=0.057). MDM-2 protein was considered to have no play as a prognostic factor. Conclusion :In the gastric adenocarcinoma, p53 protein expression seemed to have a inverse relationship with clinical outcomes but MDM-2 protein expression, which was observed more frequently than those of p53, seemed not to be prognostic indicator.